A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma

Trial Profile

A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Indacaterol/mometasone (Primary) ; Mometasone; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis; Novartis Pharma A.G.
  • Most Recent Events

    • 30 Sep 2016 Planned End Date changed from 1 Aug 2018 to 1 Oct 2018.
    • 30 Sep 2016 Planned primary completion date changed from 1 Aug 2018 to 1 Oct 2018.
    • 08 Apr 2016 Planned End Date changed from 1 Apr 2018 to 1 Aug 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top